Frequently Asked Questions
GDT and the Future of Diabetes Cure Treatment
A clear guide to the science, real-world applications, and token ecosystem
Technology
Yes. Token balances, burn activity, trial updates, and ESG impact metrics will be published quarterly, with annual third-party audits and blockchain-verified data for transparency.
Personal data is stored only for the legally required period, then securely deleted. It is never repurposed for marketing or shared with third parties without consent.
The project enforces strict KYC/AML checks, complies with all relevant crypto and healthcare regulations, and follows medical advertising laws to avoid unverified claims.
The core ingredient, 5-ALA, is already widely available as a supplement with a strong safety profile. Biozipcode™ delivery aims to further minimize risks by targeting only diseased cells. However, full safety confirmation will come from ongoing clinical trials.
Patients will be able to join “Diabetes Cure Tours” in Palau, UAE, or Japan. These medical tourism programs combine treatment with long-term wellness stays and are paid for using GDT (or cash though GDT).
A Phase IIa trial has already shown significant improvement in patients with diabetes. The next step is to confirm complete remission in larger multi-country trials.
Unlike conventional treatments that focus on blood sugar management, this therapy aims to eliminate the root cause of diabetes—abnormal stem cells—offering the potential for complete remission.
2026–2027:
Multi-site trials in Palau, UAE, and Japan; pilot medical tourism
2028–2029:
Phase III trials in UAE, Japan, and the U.S.; regulatory submissions
2030:
Global rollout with ~20,000 medical tourism patients annually
Biozipcode™ uses a unique 7-amino-acid “cell postal code” that delivers drugs only to the intended target cells, preventing exposure to healthy tissues. This greatly reduces side effects while maintaining high efficacy.
The project aims to prove a complete cure for diabetes by targeting and eliminating abnormal hematopoietic stem cells, known as Diabetes Stem Cells (DSCs), using a combination of HDAC inhibitors, 5-ALA, and Biozipcode™ drug delivery technology.
Token
GDT can be used for:
- Priority access to high-end curative diabetes tourism packages
- Payment for medical tourism services in the UAE, Palau, and Japan
- Purchase of 5-ALA supplements and formulations
- Biomarker testing for DSC detection
Online consultations with specialist physicians Additionally, 20% of tokens used for medical services are burned to reduce supply.
GDT is a pure utility token directly tied to real-world services such as curative diabetes tourism, biomarker testing, and specialist consultations. Unlike speculative tokens, it is backed by a scientific project targeting complete remission of diabetes through HDAC inhibitors, 5-ALA, and Biozipcode™ drug delivery technology. It is not a security and offers no dividends or ownership rights.
Yes. Token balances, burn activity, trial updates, and ESG impact metrics will be published quarterly, with annual third-party audits and blockchain-verified data for transparency.
Personal data is stored only for the legally required period, then securely deleted. It is never repurposed for marketing or shared with third parties without consent.
The project enforces strict KYC/AML checks, complies with all relevant crypto and healthcare regulations, and follows medical advertising laws to avoid unverified claims.
GDT is structured as a utility token for service payments and participant rewards. It is designed to avoid classification as a security in all operating jurisdictions, with legal opinions obtained though lawyers in BVI, UAE, Japan, and the U.S.
Key risks include clinical trial failure, regulatory delays, and potential declines in medical tourism demand. The project mitigates these with multi-country trials, adaptive trial designs, parallel regulatory filings, and diversified service offerings.
2026–2027:
Multi-site trials in Palau, UAE, and Japan; pilot medical tourism
2028–2029:
Phase III trials in UAE, Japan, and the U.S.; regulatory submissions
2030:
Global rollout with ~20,000 medical tourism patients annually
A total of 500 million GDT will be minted at launch, with no future issuance. Allocation includes 30% to early investors, 20% to the public sale, 20% for staking/rewards, 10% to the team, 10% to liquidity pools, and 10% to an SDG public fund.
GDT is required for payments in medical tourism, biomarker testing, and 5-ALA supplement purchases. Real-world healthcare demand ensures continuous token usage, and 20% of tokens used for medical services are permanently burned, reducing supply over time.
GDT is a blockchain-based utility token that grants access to specific healthcare services—such as curative diabetes treatment programs, biomarker testing, medical tourism, and specialist consultations—within the Biozipcode Group ecosystem. It is not a security, and it does not provide dividends, interest, or voting rights.
Terms
The Biozipcode Group is a project team led by Biozipcode, Inc. (Japan), composed of multiple affiliated companies and institutions involved in medical research, pharmaceutical development, business implementation, international collaboration, and token operations. Research and development are carried out in partnership with academic institutions in Japan, while manufacturing and implementation are handled by partner companies in the UAE, Japan, the United States, and Palau. The token is issued by Auring Inc., a corporation registered in the British Virgin Islands (BVI).
Utility Token
A blockchain-based token that grants access to specific services—such as paying platform fees, unlocking premium features, or settling medical-tour payments—without conferring dividends or voting rights. Its value is driven mainly by actual demand and limited supply; regulatory frameworks usually treat it as non-security when properly structured.
Security Token
A digital asset representing an investment contract with profit-sharing or ownership claims, similar to stocks or bonds. Issuers must comply with securities regulations—prospectus filing, investor limits, and disclosure—despite using blockchain for transfer and custody.
Biozipcode™ is a peptide-based drug delivery technology that attaches a “cell-specific postal code” to drugs or diagnostic probes, enabling them to reach only the intended target cells.
From combinations of 20 amino acids, seven-digit sequences are designed—yielding over 1.3 billion theoretical combinations—and a code is selected that can be uniquely recognized by the target cell.
When a drug or probe is tagged with this code, it circulates through blood or cerebrospinal fluid without interacting with other tissues. Once it reaches the target cell, membrane receptors recognize the code and initiate uptake.
As a result, the system maximizes therapeutic efficacy while minimizing side effects.
Currently, the technology is being explored for multiple applications, including curative therapies for diabetes (via abnormal hematopoietic stem cell reset), low-toxicity cancer and autoimmune disease treatments, and high-precision biomarker detection.
A Diabetic Stem Cell refers to a research term describing hematopoietic stem cells in the bone marrow that become epigenetically abnormal when exposed to high blood glucose levels.
Under normal conditions, hematopoietic stem cells produce blood cells and support tissue repair throughout the body. However, in hyperglycemic environments, the expression of histone deacetylases (HDACs) becomes dysregulated, causing these cells to transform into diabetes-specific abnormal hematopoietic stem cells. These cells circulate through the bloodstream, migrate to multiple organs such as nerves, kidneys, bones, and liver, and cause chronic inflammation and tissue damage—thereby reinforcing the persistent, “incurable” nature of diabetes.
Recent mouse studies (e.g., Communications Biology, 2023) demonstrated that short-term co-administration of HDAC inhibitors and insulin can reset these abnormal stem cells. Even after stopping the treatment, blood glucose levels remained in the normal range, resulting in complete remission.
Furthermore, in experiments targeting and removing CD106-positive short-term hematopoietic stem cells, dramatic improvement was observed in complications such as diabetic neuropathy.
In essence, “curing diabetes” means more than just lowering blood glucose—it involves normalizing the abnormal stem cells that trigger the disease and breaking the cycle of recurrence.
If similar results are confirmed in human trials, this could fundamentally transform conventional diabetes care, which relies on insulin injections and complication management, and would represent a major breakthrough in the field.
